Zealand Pharma to Host Third‑Quarter 2025 Conference Call on 13 November
Zealand Pharma A/S (NASDAQ: ZEAL), the Danish biotechnology firm that specialises in peptide‑based therapeutics, has scheduled a conference call for 13 November at 2 pm CET (8 am ET). The call will present the company’s third‑quarter 2025 financial results and will be led by President and CEO Adam Steensberg, CFO Henriette Wennicke, and CMO David Kendall. Investors can register for the dial‑in or listen‑only webcast at the company’s website, with the full presentation and a post‑call recording to be made available thereafter.
Corporate Actions and Share Capital Developments
In the run‑up to the earnings call, Zealand Pharma has completed several corporate actions that underscore its growth strategy:
| Date | Event |
|---|---|
| 11 September 2025 | Increase in share capital following the exercise of employee warrants |
| 24 September 2025 | Appointment of Rachel James‑Owens as Vice President, Corporate Communications & Media Relations |
| 30 September 2025 | Publication of total shares and voting rights; a major shareholder announcement for Van Herk Investments B.V. was also disclosed |
These moves signal a concerted effort to strengthen the company’s capital base and enhance shareholder engagement ahead of the upcoming Capital Markets Day in London on 11 December 2025.
Market Context
With a market cap of 30.6 bn DKK, a price‑to‑earnings ratio of 4.63, and a 52‑week trading range from 306.1 DKK to 893 DKK, Zealand Pharma remains a focused player in the biotechnology sector, targeting gastrointestinal and metabolic diseases through a pipeline of late‑stage peptide therapeutics. The company’s close price of 427 DKK as of 6 November 2025 positions it well for a potential upside should the forthcoming results validate its clinical and commercial trajectory.
Forward‑Looking Outlook
The forthcoming earnings presentation is expected to provide critical insight into the company’s financial health, cash generation, and progress on its clinical portfolio. Analysts and investors will be keen to assess:
- Cash Position and Burn Rate – How the company balances its R&D expenditures against its cash runway, especially in light of the recent share‑capital expansion.
- Clinical Milestones – Any updates on gastrointestinal or metabolic indications that could accelerate the pipeline’s transition into the market.
- Revenue Forecasts – Whether the company will revise its guidance upward, reflecting the momentum behind its peptide therapeutics pipeline.
Given Zealand Pharma’s historically disciplined operating metrics and its position within a niche therapeutic area, a positive earnings report could reinforce investor confidence and support a rally in the shares leading up to the December 11 Capital Markets Day.
Investors are encouraged to attend the conference call or review the post‑call recording to gain a comprehensive understanding of Zealand Pharma’s current standing and future prospects.
